Skip to Content

Cinvanti (aprepitant) Disease Interactions

There is 1 disease interaction with Cinvanti (aprepitant):


Aprepitant (Includes Cinvanti) ↔ liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Aprepitant is primarily metabolized by the liver. In studies of patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9), aprepitant was well tolerated and no clinically significant alterations in its pharmacokinetics were observed. Thus, no dosage adjustment of aprepitant is necessary in this patient population. However, there are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score > 9), and caution is advised if aprepitant is used in such patients.


  1. "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.

Cinvanti (aprepitant) drug interactions

There are 544 drug interactions with Cinvanti (aprepitant)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.